

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050



January 11, 2019

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited.,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.
BSE Code– 524715

NSE Code – SUNPHARMA

Dear Sirs,

Sub: Updates

We refer to our press release dated September 14, 2018 regarding “Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension”.

Further to the above, we wish to inform you that Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) has commercialised XELPROS™ (Latanoprost ophthalmic emulsion) 0.005%, in US.

The Company had in-licensed XELPROS™ from Sun Pharma Advanced Research Company Limited (“SPARC”) in June 2015 and this commercialization of XELPROS™, has triggered a milestone payment of USD 10 Million and sales linked royalties, by the Company to SPARC.

This is for your information and record.

Thanking you,

Yours faithfully,

For Sun Pharmaceutical Industries Ltd.,

Ashok Bhuta

Compliance Officer